方法文章

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

DOI:

10.3791/59820

2019年6月30日

本文内容

摘要

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

We characterized a new kinase protein using robust biochemical approaches: Western Blot analysis with a dedicated specific antibody on different cell lines and tissues, interactions by coimmunoprecipitation experiments, kinase activity detected by Western Blot using a phospho-specific antibody and by γ[32P] ATP labeling.

摘要

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Extensive whole genome sequencing has identified many Open Reading Frames (ORFs) providing many potential proteins. These proteins may have important roles for the cell and may unravel new cellular processes. Among proteins, kinases are major actors as they belong to cell signaling pathways and have the ability to switch on or off many processes crucial to the fate of the cell, such as cell growth, division, differentiation, motility, and death.

In this study, we focused on a new potential kinase protein, LIMK2-1. We demonstrated its existence by Western Blot using a specific antibody. We evaluated its interaction with an upstream regulating protein using coimmunoprecipitation experiments. Coimmunoprecipitation is a very powerful technique able to detect the interaction between two target proteins. It may also be used to detect new partners of a bait protein. The bait protein may be purified either via a tag engineered to its sequence or via an antibody specifically targeting it. These protein complexes may then be separated by SDS-PAGE (Sodium Dodecyl Sulfate PolyAcrylamide Gel) and identified using mass spectrometry. Immunoprecipitated LIMK2-1 was also used to test its kinase activity in vitro by γ[32P] ATP labeling. This well-established assay may use many different substrates, and mutated versions of the bait may be used to assess the role of specific residues. The effects of pharmacological agents may also be evaluated since this technique is both highly sensitive and quantitative. Nonetheless, radioactivity handling requires particular caution. Kinase activity may also be assessed with specific antibodies targeting the phospho group of the modified amino acid. These kinds of antibodies are not commercially available for all the phospho modified residues.

引言

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

For many decades, numerous signaling pathways have been elucidated and their involvement in crucial cellular processes such as cell division, differentiation, motility, programmed cell death, immunity and neurobiology, has been shown. Kinases play a significant role in these signaling pathways as they often finely regulate their activation or inactivation and are part of transient versatile complexes that respond to external stimuli1,2,3. Mutation and dysregulation of kinases often lead to diseases in humans, and they have therefore become one of the most important drug targets over the past forty years4.

In this context, it is important to be able to detect kinase interaction with their upstream regulators or downstream substrates and to identify new partners. Affinity purification and immunoprecipitation are very powerful techniques for the isolation of protein complexes5. The bait protein or kinase may be tagged with a specific peptide sequence allowing the use of commercial beads covalently coupled with antibodies targeting the peptide. This material permits a high reproducibility in experiments6,7,8. Endogenous proteins may also be immunoprecipitated using antibodies targeting directly the bait protein. The antibodies may be cross-linked to Protein A or Protein G agarose beads or simply incubated with these beads prior to adding lysate. Lysis buffers must be optimized to allow protein solubilization without losing interaction and to avoid protein degradation. A major drawback of this approach is that the interaction is detected upon cell lysis; therefore, transient or weak interactions, together with those requiring subcellular context may be missed. Other techniques may be used to work directly in the cell such as Proximity Ligation Assay (PLA)9, in vivo cross-linking-assisted affinity purification (XAP)10, Bioluminescence Resonance Energy Transfer (BRET) or Förster Resonance Energy Transfer (FRET)11,12. Furthermore, immunoprecipitation is not appropriate to determine the thermodynamic constants of the binding, for which physical techniques such as Surface Plasmon Resonance, Isothermal Titration Calorimetry or Microscale Thermophoresis are required13,14.

Kinase activity may be assessed using multiple techniques. Herein, we focused on phospho-specific antibodies and in vitro γ[32P] ATP (Adenosine TriPhosphate) labeling. Phospho-specific antibodies target the phosphate modification of a particular residue within a protein. They may be used in Western Blot or ELISA (Enzyme-Linked ImmunoSorbent Assay) after cell lysis, for immunohistochemistry, and also on intact cells using flow cytometry or immunofluorescence. Their drawbacks may include their lack of specificity, which can be evaluated using a mutated version of the target protein, and their not being commercially available for all proteins. In vitro γ[32P] ATP labeling is a very robust, well-established and highly sensitive method15. Immunoprecipitated or recombinant proteins may be used, and different substrates may be tested. The effects of drugs may also be assessed as this method is quantitative. Its major drawback is that the radioactivity associated with the approach requires handling with caution. Alternative methods are also possible based on the measurement of fluorescent or luminescent peptide substrates and taking advantage of altered fluorescent/luminescent properties upon phosphorylation. Such methods also allow high throughput, which is required, for example, in the screening of molecules that may be potential inhibitors of the target kinase. Indeed, kinases represent one of the largest classes of drug targets pursued by pharmaceutical companies16.

In this study, we focused on the LIMK2-1 protein (LIMK2-1 stands for Lin11, Isle1, Mec3 Kinase isoform 2-1). The LIMK2 kinase protein was first described in 199517. Three isoforms of LIMK2 are produced by alternative splicing: LIMK2a, LIMK2b and LIMK2-1. At present, LIMK2-1 has only been described at the mRNA level in a single study18. Herein, we characterize this potential new kinase protein at the molecular level using robust biochemical approaches. Firstly, we demonstrate that LIMK2-1 is indeed synthesized. Similar to its two counterparts, LIMK2a and LIMK2b, it interacts with the upstream kinase ROCK (Rho-associated protein kinase). We show LIMK2-1 has a kinase activity on Myelin Basic Protein (MBP), but not on cofilin, the canonical substrate of LIM kinases.

访问受限。请登录或开始试用以查看此内容。

方案

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

1. Cell preparation for transfection

CAUTION: All the steps of the cell culture must be performed in a dedicated laboratory, and cells are manipulated within a Class 2 microbiological cabinet.

  1. Seed HEK-293 (Human Embryonic Kidney) cells in Ø 10 cm plates in 10 mL of DMEM (Dulbecco's Modified Eagles Medium) supplemented with 10% fetal calf serum. Culture for 3 to 5 days under 5% CO2, at 37 °C, until the cells reach ~90% confluence.
  2. Treat Ø 10 cm plates with Collagen R to increase cell adhesion to the plastic plates.
    1. Add 5 mL of a solution of Collagen R, 200-fold diluted in Phosphate Saline Buffer (PBS) in a Ø 10 cm plate. Overlay the liquid over the whole surface of the plate.
    2. Incubate at room temperature for at least 1 h within the biosafety cabinet.
    3. Remove collagen solution, and discard it. Add 5 mL of PBS, spread it all over the surface of the plate, remove it and discard it. Repeat this wash once.
    4. Add 8 mL of DMEM supplemented with 10% fetal calf serum. Keep the prepared plates within the biosafety cabinet.
  3. Take HEK-293 plates from step 1.1 within the biosafety cabinet. Remove the medium from the plates and discard it in a dedicated bleach trash. Add 2 mL of supplemented DMEM, and flush the cells to detach them using the flow of a 1 mL micropipette, taking care to avoid making foam.
  4. Collect the cells in a 15 mL tube and add 4 mL of supplemented DMEM. Homogenize with a 10 mL pipette, by pipetting up and down 3 times.
  5. Take 2 mL of this cell solution and add them to collagen-treated plates containing supplemented DMEM from step 1.2.4.
  6. Grow for 24 hours in the incubator at 5% CO2 and 37 °C. Cells should be 50-80% confluent at the time of transfection.

2. Transient transfections

  1. Remove the medium from the plates, discard it in a dedicated bleach trash, and add 10 mL of fresh supplemented DMEM. Put back the plates into the incubator at 37 °C while preparing the transfection mixture.
  2. In a 15 mL tube, add 450 μL of a 10 mM Tris-HCl pH 7.5/1 mM EDTA (Tris stands for Tris(hydroxymethyl)aminomethane, and EDTA for ethylenedinitrilotetraacetic acid) solution and 50 μL of a 2.5 M CaCl2 solution. Mix by inversion.
  3. Add 10 μg of plasmidic DNA (Deoxyribonucleic acid) prepared from a midi preparation on a liquid culture of bacteria transformed with the dedicated plasmid. Mix by inversion.
  4. Under smooth agitation on a vortex, add 500 μL of BES buffered saline 2x concentrate (composition: BES, 10.7 g/L, NaCl, 16.0 g/L, Na2HPO4, 0.27 g/L; BES stands for N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid, N,N-Bis(2-hydroxyethyl)taurine) slowly drop by drop.
  5. Incubate for at least 15 min (up to 45 min) at room temperature within the biosafety cabinet. Do not vortex, do not mix! Move the tubes very carefully not to disturb the complex formation between DNA and calcium phosphate.
  6. Take the plates from step 2.1 to the safety cabinet. Add the DNA complexes very carefully, drop by drop, onto the cells all over the surface of the plate.
  7. Incubate for 24 to 72 hours in the incubator at 37 °C. Usually maximum protein expression is reached within 48 hours.

3. Lysis

NOTE: Work on ice, and with cold buffers to prevent protein degradation.

  1. Prepare lysis buffer: 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM EDTA, 0.1% Triton X-100, 50 mM NaF, 10 mM sodium pyrophosphate, 1 mM Na3VO4, 20 mM p-nitrophenyl phosphate, 20 mM β-glycerophosphate, 10 μg/mL aprotinin, 0.05 μg/mL okaidic acid, 1 μg/mL leupeptin, and 1 mM PMSF (phenylmethylsulfonyl fluoride). Around 4 mL of lysis buffer are required for each transfected plate.
  2. Remove plates with transfected cells from the incubator. Put them on ice.
    NOTE: From this step, it is possible to work on a “normal” bench.
  3. Remove the media, and discard it in a dedicated bleach trash.
  4. Wash twice with 3 mL of cold PBS: add 3 mL of PBS on the side of the plate drop by drop to avoid detaching transfected cells, spread all over the surface of the plate, remove PBS and discard it; repeat this step once more. At the end, remove carefully the rest of PBS by tilting the plate to prevent lysis buffer dilution for next step.
  5. Add 500 μL of cold lysis buffer on the transfected washed cells. Spread it all over the surface of the plate.
  6. Incubate for 10 min on ice. From time to time (at least twice), spread again the buffer all over the surface of the plate.
  7. Scrap the cells and collect them in a microcentrifuge tube.
  8. Centrifuge for 10 min at 10,000 x g at 4 °C.
  9. Collect supernatant in a new microcentrifuge tube. This fraction corresponds to the lysate (whole cell extract). Discard the pellet which corresponds to cell membrane debris.
  10. Collect an aliquot of this fraction to a new microcentrifuge tube (around 50 μL). This fraction corresponds to the “TOTAL fraction” or “Cell Lysate” or “Whole Cell extract” allowing analysis of whether transfected proteins are expressed by Western Blot.
    NOTE: At this point, samples can be directly used for Western Blot analyses. Laemmli buffer must be added to the sample, which is then heated at 95 °C for 5 min, centrifuged at 10,000 x g for 5 min, and loaded on appropriate SDS-PAGE. Samples may also be stored at -80 °C.

4. Immunoprecipitation

  1. Gently resuspend agarose beads coupled with the appropriate antibody: HA (Human influenza hemagglutinin), Flag, or GFP (Green Fluorescent Protein) by smooth inversion.
  2. Cut the end of a 200 μL tip from a micropipette to allow beads to enter the tip. Pipette the beads up and down several times to saturate the tip to ensure to take the correct volume of beads.
  3. Take 40 μL of beads in a microcentrifuge tube.
  4. Add 500 μL of TENET (30 mM Tris-HCl pH 7.5, 120 mM NaCl, 5 mM EDTA, 1% Triton X-100) buffer. Mix by inversion. Centrifuge for 2 min at 1,000 x g at 4 °C. Remove carefully supernatant and discard it. Add 500 μL of TENET. Incubate for at least 1 hour at 4 °C on a rotating wheel.
    NOTE: This pre-incubation step in TENET allows to reduce non-specific interactions and so to decrease background signal.
  5. Wash the beads twice with 500 μL of lysis buffer.
    1. Centrifuge 2 min at 1,000 x g at 4°C.
    2. Remove carefully supernatant buffer, and discard it.
      NOTE: Take care not to aspirate beads during these washing steps.
    3. Add 500 μL of lysis buffer. Homogenize by inverting the tube.
    4. Repeat steps 4.5.1- 4.5.3.
  6. Centrifuge for 2 min at 1,000 x g at 4°C. Carefully remove supernatant buffer, and discard it.
  7. Incubate beads with the lysate from step 3.9 for 2 to 4 hours at 4 °C on a rotating wheel.
  8. Wash immunoprecipitated beads.
    NOTE: At this point, the immunoprecipitated beads may be washed five times with the lysis buffer, and then eluted with Laemmli buffer. The eluate may be used for Western Blot analyses or stored at -80 °C. Alternatively, beads may be washed twice with the lysis buffer and then three times with the kinase buffer to perform γ[32P] ATP labeling.

5. Coimmunoprecipitation analyses

  1. Wash immunoprecipitated beads from step 4.7 with the lysis buffer.
    1. Centrifuge for 2 min at 1,000 x g in a refrigerated centrifuge at 4 °C.
    2. Carefully remove the supernatant, and discard it.
    3. Add 500 μL of lysis buffer. Homogenize by inverting the tube.
    4. Repeat steps 5.1.1-5.1.3 four times.
  2. Elution
    1. Centrifuge for 2 min at 1,000 x g in a refrigerated centrifuge at 4 °C.
    2. Carefully remove the supernatant, and discard it. Remove the last drops of supernatant with a Hamilton syringe in order to avoid aspiration of the beads, and discard the supernatant.
    3. Add 40 μL of 4x Laemmli buffer (200 mM Tris/HCl pH 6.8, 4% SDS, 40% glycerol, 0.5 M β-mercaptoethanol, 0.02% bromophenol blue). Homogenize by gently tapping the tube.
    4. Incubate for 5 min at room temperature.
    5. Centrifuge for 5 min at 10,000 x g at room temperature.
    6. With a Hamilton syringe, remove the supernatant and collect it in a new microcentrifuge tube. This fraction corresponds to the “Eluate”, which may be stored at -80 °C, or directly analyzed by Western Blot.

6. Kinase assay

  1. Prepare the kinase buffer: 50 mM HEPES-NaOH pH 7.5 (HEPES stands for 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 150 mM NaCl, 5 mM MgCl2, 5 mM MnCl2, 50 mM NaF, 1 mM Na3VO4, 20 mM β-glycerophosphate, 1 μg/mL leupeptin, and 1 mM PMSF. Around 2 mL of the kinase buffer is required for each immunoprecipitation condition.
  2. Wash immunoprecipitated beads from step 4.7 twice with 500 μL of lysis buffer.
    1. Centrifuge for 2 min at 1,000 x g in a refrigerated centrifuge at 4 °C.
    2. Carefully remove supernatant, and discard it. Add 500 μL of lysis buffer. Homogenize by inversion.
    3. Repeat steps 6.2.1 and 6.2.2.
  3. Wash immunoprecipitated beads three times with 500 μL of kinase buffer.
    1. Centrifuge for 2 min at 1,000 x g in a refrigerated centrifuge at 4 °C.
    2. Carefully remove supernatant, and discard it. Add 500 μL of kinase buffer. Homogenize by inversion.
    3. Repeat steps 6.3.1 and 6.3.2 twice.
  4. Centrifuge for 2 min at 1,000 x g in a refrigerated centrifuge at 4 °C.
  5. Carefully remove supernatant, and discard it. Remove the last drops of supernatant with a Hamilton syringe in order to avoid aspiration of the beads, and discard the supernatant.
  6. Add 40 μL of kinase buffer to the immunoprecipitated beads. Resuspend the beads by gently tapping the tube.
  7. Prepare the mix for the γ[32P] ATP labeling (final volume is 22.5 μL, complete with kinase buffer) in a safe lock-tube.
    1. Add the required volume of kinase buffer to reach a final volume of 22.5 μL.
    2. Cut the end of a 20 μL tip of a micropipette. Resuspend the immunoprecipitated beads from step 6.6 by pipetting up and down several times. Collect 10 μL of these beads into the safe-lock tube.
    3. Add ATP from a 10 μM stock solution to reach 50 mM of finale concentration. According to the number of sample treated, a dilution of the stock solution of ATP in the kinase buffer is suggested to allow to pipette 1 to 2 μL, to be sure the volume is correct.
    4. Add 2.5 μg of substrate (cofilin or Myelin Basic Protein, MBP in the present study case).
  8. Add 5 μCi of γ[32P] ATP (3,000 Ci/mmol) to initiate the reaction. Mix by pipetting up and down slowly.
    CAUTION: From this point, work must be done in a safety place dedicated for radioactivity manipulations with cautious precaution, dedicated protections and appropriate controls (radioactive shields, Geiger counter, specific waste collect, personal breast and finger badges to detect radioactive exposure, filter tips).
  9. Incubate for 20 min at 30 °C.
  10. Stop the reaction with 6 μL of 5x Laemmli buffer.
  11. Heat at 95° C for 5 min.
  12. Centrifuge at 10,000 x g for 5 min at room temperature.
  13. Load on a SDS-PAGE. Proceed to migration.
    NOTE: Take care that the front line of free γ[32P] ATP does not exit the gel to avoid contamination of the migration tank.
  14. Stain the gel at room temperature.
    1. Remove the gel from the glass plates.
    2. Proceed with three baths in water at room temperature.
    3. Stain the gel overnight with Coomassie Blue at room temperature.
    4. Destain the gel with several wash baths with water at room temperature.
  15. Wrap the gel with plastic wrap.
  16. Expose for one night or more on a phosphorimager screen.
  17. Read the screen on a phosphorimager to detect labeled bands.

访问受限。请登录或开始试用以查看此内容。

结果

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

LIMK2-1 protein is synthesized
LIMK2-1 is mentioned in databanks, but thus far only one paper has shown the existence of its mRNA18. Compared to its two homologs, LIMK2a and LIMK2b, LIMK2-1 has an extra C-terminal domain identified as a Protein Phosphatase 1 Inhibitory domain (PP1i). We designed an antibody that targets a peptide of this domain, amino acids 671-684 (Figure 1A).
BLAST research against human prot...

访问受限。请登录或开始试用以查看此内容。

讨论

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Herein, we have used robust biochemical tools to characterize at the molecular level a new protein, LIMK2-1, believed to be a kinase based on its sequence and on its homologs, LIMK2a and LIMK2b20.

Firstly, we demonstrated the existence of LIMK2-1 at the protein level using Western Blot analysis with a specific antibody. Following this, we evaluated its interaction with the upstream kinase ROCK1, which is known to regulate LIMK2a and LIMK2b, the homologs of LIMK2-1. Fina...

访问受限。请登录或开始试用以查看此内容。

披露

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The authors have nothing to disclose.

致谢

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

This work was supported by La Ligue contre le Cancer, l’Association Neurofibromatoses et Recklinghausen, and la Région Centre Val de Loire. Many thanks to Aurélie Cosson and Déborah Casas for flow cytometry data, and to Keyron Hickman-Lewis for thorough proofreading of the manuscript.

访问受限。请登录或开始试用以查看此内容。

材料

本文使用的材料清单
姓名公司目录编号评论
抗肌动蛋白Sigma-AldrichA1978用于 Western Blot
抗体 抗 c-MycInvitrogenMA1-21316用于 Western Blot
抗体 抗丝切蛋白细胞信号传导技术3312/5175用于 Western Blot
抗体 GFP抗体 Santa Cruzsc-9996用于 Western Blot
抗体 抗 HARocheWesternBlot11687423001
抗磷酸化丝切蛋白细胞信号传导技术3313用于 Western Blot
抗体 抗 PP1iEurogentec专为本研究设计Western Blot
抑肽酶EuromedexA-162B用于裂解缓冲液
ATPInvitrogenPV3227用于 γ[32P] 标签
γ[32P] ATPPerkin ElmerNEG502A为 γ[32P] 标记
BES 缓冲盐水Sigma-Aldrich14280用于转染
β-甘油磷酸盐Sigma-AldrichG9422用于裂解和激酶缓冲液
β-巯基乙醇Sigma-AldrichM3148用于 Laemmli
BSASigma-AldrichA3059用于封闭缓冲液
溴酚蓝Sigma-AldrichB0126用于 Laemmli
CaCl2Sigma-AldrichC3881用于转染
离心机Sigma111-541
Collagen RPan BiotechP06-20166用于转染
对照 siRNAAmbionAM4611用于 PP1i 抗体特异性
考马斯 PageBlue 蛋白质染色液Thermo-Fisher24620用于凝胶染色
EDTASigma-Aldrich3690用于裂解缓冲液
电泳单元BioradMini-Protean用于蛋白质印迹
EZview Red 抗 HA 亲和凝胶Sigma-AldrichE6779用于免疫沉淀
GeneSys 软件Ozyme用于 Western Blot 采集
GeneTolls 软件Ozyme用于 Western Blot 定量
GFP 捕获珠Chromtek用于免疫沉淀
甘氨酸Euromedex26-128-6405用于转移缓冲液
GST-cofilinUpstate Cell 信号传导12-556用于 γ[32P] 标记
汉密尔顿注射器 100 mLHamilton710小心地从珠子中取出上清液而不吸出
HEPESSigma-AldrichH3375用于激酶缓冲液
ImageQuant TL 软件GE Healthcare用于放射性采集和定量
LIMK2 siRNAAmbions8191用于 PP1i抗体特异性
的亮肽素Sigma-AldrichSP-04-2217和激酶缓冲液
MBPUpstate Cell 信号转导13-173用于 γ[32P] 标记
MgCl2Sigma-AldrichM8266用于激酶缓冲液
MnCl2Sigma-Aldrich244589,用于激酶缓冲液
NaClEuromedex1112和激酶缓冲液
NaFSigma-AldrichS-1504用于裂解和激酶缓冲液
Okaidic酸性Euromedex0-2220用于裂解缓冲液
PMSFSigma-Aldrich78830用于裂解和激酶缓冲液
对硝基苯磷酸酯Euromedex1026用于裂解缓冲液
PVDF 膜 Immobillon-PMerck-MilliporeIPVH00010孔径 0.45 mm,用于蛋白质印迹
旋转轮Labinco用于微珠孵育
安全锁 eppendorfEppendorf0030120.086用于激酶测定
SDSSigma-Aldrich5030用于 Laemmli 和迁移缓冲液
原钒酸钠LC LaboratoriesS8507用于裂解和激酶缓冲液
焦磷酸钠Fluka71501用于裂解缓冲液
Super Signal West Dura蛋白生物学34075用于 Western Blot
Syngene PxiOzyme用于 Western Blot
组织提取物

 
生物链

 
P1234035 脑
P12345152 肺
P1234149 肝脏
P1234188 胰腺
P1234260 用于
蛋白质印迹分析的睾丸

 
转移装置BioradMini-Trans-Blot,用于蛋白质印迹
TrisEuromedex26-128-3094 B用于裂解缓冲液
Tween-20Sigma-AldrichP7949用于封闭缓冲液
台风 FLA9500GE Healthcare读取放射自显影
台风 TrioAmersham Bioscience读取放射自显影
Whatman 论文GE Healthcare3030-672用于 Western Blot
抗体应用科学 用于 它们 :用于裂解,,,用于裂解的 ,

参考文献

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,
  1. Manning, G., Plowman, G. D., Hunter, T., Sudarsanam, S. Evolution of protein kinase signaling from yeast to man. Trends in Biochemical Sciences. 27, 514-520 (2002).
  2. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., Sudarsanam, S. The protein kinase complement of the human genome. 298, Science. New York, N.Y. 1912-1934 (2002).
  3. Ochoa, D., Bradley, D., Beltrao, P. Evolution, dynamics and dysregulation of kinase signalling. Current Opinion in Structural Biology. 48, 133-140 (2018).
  4. Bhullar, K. S., et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Molecular Cancer. 17, 48(2018).
  5. Kaboord, B., Perr, M. Isolation of proteins and protein complexes by immunoprecipitation. Methods in Molecular Biology. 424, Clifton, N.J. 349-364 (2008).
  6. Arnau, J., Lauritzen, C., Petersen, G. E., Pedersen, J. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. Protein Expression and Purification. 48, 1-13 (2006).
  7. Wood, D. W. New trends and affinity tag designs for recombinant protein purification. Current Opinion in Structural Biology. 26, 54-61 (2014).
  8. Young, C. L., Britton, Z. T., Robinson, A. S. Recombinant protein expression and purification: a comprehensive review of affinity tags and microbial applications. Biotechnology Journal. 7, 620-634 (2012).
  9. Greenwood, C., et al. Proximity assays for sensitive quantification of proteins. Biomolecular Detection and Quantification. 4, 10-16 (2015).
  10. Wang, X., Huang, L. Dissecting Dynamic and Heterogeneous Proteasome Complexes Using In vivo Cross-Linking-Assisted Affinity Purification and Mass Spectrometry. Methods in Molecular Biology. 1844, Clifton, N.J. 401-410 (2018).
  11. Raykova, D., et al. Let There Be Light! Proteomes. 4, (2016).
  12. Weibrecht, I., et al. Proximity ligation assays: a recent addition to the proteomics toolbox. Expert Review of Proteomics. 7, 401-409 (2010).
  13. Podobnik, M., et al. How to Study Protein-protein Interactions. Acta Chimica Slovenica. 63, 424-439 (2016).
  14. Rao, V. S., Srinivas, K., Sujini, G. N., Kumar, G. N. Protein-protein interaction detection: methods and analysis. International Journal of Proteomics. 2014, 147648(2014).
  15. Peck, S. C. Analysis of protein phosphorylation: methods and strategies for studying kinases and substrates. The Plant Journal: For Cell and Molecular Biology. 45, 512-522 (2006).
  16. Jia, Y., Quinn, C. M., Kwak, S., Talanian, R. V. Current in vitro kinase assay technologies: the quest for a universal format. Current Drug Discovery Technologies. 5, 59-69 (2008).
  17. Okano, I., et al. Identification and characterization of a novel family of serine/threonine kinases containing two N-terminal LIM motifs. The Journal of Biological Chemistry. 270, 31321-31330 (1995).
  18. Croft, D. R., et al. p53-mediated transcriptional regulation and activation of the actin cytoskeleton. Cell Research. 21, 666-682 (2011).
  19. Tastet, J., et al. LIMK2-1 is a Hominidae-Specific Isoform of LIMK2 Expressed in Central Nervous System and Associated with Intellectual Disability. Neuroscience. 399, 199-210 (2019).
  20. Vallee, B., et al. LIMK2-1, a new isoform of human LIMK2, regulates actin cytoskeleton remodeling via a different signaling pathway than that of its two homologs, LIMK2a and LIMK2b. The Biochemical Journal. 475, 3745-3761 (2018).
  21. Lee, Y. C., et al. Impact of Detergents on Membrane Protein Complex Isolation. Journal of Proteome Research. 17, 348-358 (2018).

访问受限。请登录或开始试用以查看此内容。

重印与许可

申请许可以重复使用本 JoVE 文章的文本或图表

申请许可

标签

SDS PAGE P32 ATP LIMK2 1 ROCK

相关文章